Lucknow Speciality Pharma

Dacomitinib Tablets 30 mg
Dacomitinib Tablets is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Dacomitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. To get access, please contact Patient Support Team @ +91 9760014849 / 9555306364 / 9794360370 / 9140551027, Time 9 am - 8 pm IST or send us a request on email (urgent@lucknowpharma.com) / WhatsApp for the same.
Get Access Price
WhatsApp

Dacomitinib Tablets was approved for medical use in the United States in 2018. It is on the World Health Organization’s List of Essential Medicines.

Dacomitinib Tablets Available Price In Lucknow Banaras Nepal

Dacomitinib Tablets

  • Generic Brand Available – VIZIMPRO
  • API – Dacomitinib
  • Packaging – 30 Tablets
  • Strength – 30 mg, 45 mg

What is Dacomitinib Tablets used for?

Dacomitinib Tablets is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Dacomitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.

    Facts of Medicines

    Dacomitinib Tablets 30 mg

    STORAGE AND HANDLING

    Care should be exercised in the handling of Dacomitinib Tablets tablets should not be opened or crushed. Store permitted between 20-25°C (68-77°F).

    DOSAGE AND ADMINISTRATION
    Recommended Dosage: 45 mg orally once daily with or without food.
    Tablets: 15 mg, 30 mg, and 45 mg.

    SIDE EFFECTS

    Most common adverse reactions are (incidence >20%) diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus.

    WARNINGS AND PRECAUTIONS

    • Interstitial Lung Disease (ILD): Permanently discontinue VIZIMPRO if ILD is confirmed.
    • Diarrhea: Withhold and reduce the dose of VIZIMPRO based on the severity.
    • Dermatologic Adverse Reactions: Withhold and reduce the dose of VIZIMPRO based on the severity.
    • Embryo-Fetal Toxicity: VIZIMPRO can cause fetal harm. Advise females of reproductive potential to use effective contraception.

    FAQs – Medicine Questions

    Dacomitinib Tablets 30 mg
    What is Dacomitinib?
    Dacomitinib is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Dacomitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.
    What are ruxolitinib tablets used for?
    Ruxolitinib is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production)
    Is ruxolitinib a chemo drug?

    Jakafi is the first medicine approved by the Food and Drug Administration (FDA) for the treatment of these patients. Jakafi is not chemotherapy. It is a targeted treatment that works to help keep the production of blood cells under control.

    Where can I buy Dacomitinib Tablets?

    You can buy Dacomitinib Tablets from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

    The buyer should check the existing law in their home country before importing the product.

    What is the procedure to buy Dacomitinib Tablets?

    Patients can simply fill the order form or can send mail at info@lucknowpharma.com Patients can also send WhatsApp messages to +91-9555306364 We will reply ASAP with the details of the Dacomitinib Tablets price as well as procurement procedure.

    Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

    What is VIZIMPRO used for?
    VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test

    NEWS / UPDATES

    1. Pfizer Limited, Electronic medicines compendium (emc), [Revised on Jan 2021] [ Accessed on 2nd Dec 2021], https://www.medicines.org.uk/emc/files/pil.10354.pdf
    2. Pfizer Labs, US Food and Drug Administration, [Revised on Sept 2018] [ Accessed on 2nd Dec 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf
    3. Sally CM Lau et al; Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer; Drugs; Published on June 2019; Accessed on 02/12/2021; https://pubmed.ncbi.nlm.nih.gov/31069718/